- Shares of Synta Pharmaceuticals (SNTA -6.3%) are notably lower on the session.
- Highlights from the company's Q3 report include: Final OS results from GALAXY-1 by "early 2014;" interim and final analyses of GALAXY-2 in H2 2014 and H1 2015, respectively; ENCHANT-1 initial results at the San Antonio Breast Cancer Symposium in December; cash position at quarter's end was $53.4M (versus $100.6M as of December 31, 2012), enough to last "into Q2 2014." (PR)
- According to market chatter, Roth Capital thinks the company could have a partnership "up its sleeve."
Synta Pharmaceuticals slides after Q3 results
Nov 4 2013, 14:28 ET